A Systematic Review of Adaptive Seamless Clinical Trials for Late-Phase Oncology Development-Reference-Cited by-同舟云学术

A Systematic Review of Adaptive Seamless Clinical Trials for Late-Phase Oncology Development

Published:2024-06-11 Issue:5 Volume:58 Page:917-929
ISSN:2168-4790
Container-title:Therapeutic Innovation & Regulatory Science
language:en
Short-container-title:Ther Innov Regul Sci

Author:

Broglio Kristine,Cooner Freda,Wu Yujun,Xiao Mike,Xue X. Q.,Lowen Marina,Ikhapoh Izuagie,He Philip

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s43441-024-00670-1.pdf

Reference26 articles.

1. Arfè A, Narang C, DuBois SG, Reaman G, Bourgeois FT. Clinical development of new drugs for adults and children with cancer, 2010–2020. J Natl Cancer Inst. 2023;115(8):917–25.

2. Biotechnology Innovation Organization, Pharma Intelligence, QLS Advisors. Clinical development success rates and contributing factors 2011–2020. 2021. https://www.bio.org/clinical-development-success-rates-and-contributing-factors-2011-2020. Accessed 26 Jan 2024.

3. Center for Drug Evaluation and Research, FDA. Cancer accelerated approvals. 2024. https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals. Accessed 26 Jan 2024.

4. Parikh RB, Hubbard RA, Wang E, Royce TJ, Cohen AB, Clark AS, et al. Exposure to US cancer drugs with lack of confirmed benefit after US Food and Drug Administration accelerated approval. JAMA Oncol. 2023;9(4):567–9.

5. Center for Drug Evaluation and Research, FDA. Adaptive design clinical trials for drugs and biologics guidance for industry. 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adaptive-design-clinical-trials-drugs-and-biologics-guidance-industry. Accessed 26 Jan 2024.